-- Centerra Gold（CG.TO，CGAU）周三盘后公布，第一季度营收和调整后利润均有所增长。 该公司表示，剔除大部分一次性项目后，第一季度调整后利润增至8820万美元，合每股0.44美元，高于去年同期的2640万美元，合每股0.13美元。FactSet此前预期每股利润为0.43美元。 营收同比增长62%，从去年同期的2.995亿美元增至4.847亿美元。FactSet此前预期为3.735亿美元。 黄金总产量为68001盎司，铜总产量为1420万磅。本季度黄金销量为72935盎司，平均售价为每盎司4172美元；铜销量为1490万磅，平均售价为每磅4.48美元。公司表示，这些价格包含了与Royal Gold公司就Mount Milligan矿区流媒体协议达成的协议的影响。 “本季度我们的财务状况得到加强，现金余额增至5.43亿美元。与此同时，我们持续投资于内部增长项目，为Langeloth公司积累了营运资金，并通过股票回购和分红向股东返还了3300万美元。”首席执行官Paul Tomory表示。 公司预计2026年黄金总产量为25万至28万盎司，铜总产量预计为5000万至6000万磅。 Centerra股票在多伦多证券交易所收盘下跌0.75加元，至23.90加元。
Related Articles
Asia
Electro Optic Systems Reports Contract Backlog Growth as of March 31
Electro Optic Systems Holdings (ASX:EOS) reported a contract backlog of AU$518 million as of March 31, up 13% from the end of 2025, according to a Thursday filing with the Australian bourse.The company closed the March quarter with unrestricted cash holdings of AU$95.1 million, representing a decrease of AU$11.8 million from the end of 2025, per the filing.
$ASX:EOS
Asia
Regis Healthcare Expects Fiscal 2026 Underlying EBITDA at Top End of Guidance
Regis Healthcare (ASX:REG) said it expects fiscal 2026 underlying earnings before interest, taxes, depreciation, and amortization (EBITDA) of about AU$135 million, at the top end of guidance, according to a Thursday Australian bourse filing.Occupancy across mature homes averaged about 96% in the fiscal third quarter, per the filing.The company said it generated net refundable accommodation deposit (RAD) cash inflows of AU$44.5 million in the third quarter, taking the total net RAD cash inflows for the year to date to AU$223 million.As resident turnover occurs, the progressive repricing of existing paid-up RADs to current advertised room prices is expected to generate net operating cash inflows of about AU$400 million over time while also increasing RAD retention earnings, the company added.
$ASX:REG
Research
Research Alert: CFRA Keeps Hold Opinion On Shares Of Mondelez International
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target price of $63, raised $1, reflects a 19x multiple of projected 2027 EPS, in line with MDLZ's historical forward P/E average. We raise our 2026 EPS estimate by $0.06 to $3.08, but cut 2027's by $0.11 to $3.32. We continue to see headwinds related to chocolate and biscuits divisions, though favorable forex has been helping to a degree. MDLZ highlighted plans to stimulate growth with more promotional activity, which could boost revenues (we see an acceleration in revenues in 2027), but may come with the trade-off of narrower margins. We note that cost-saving efforts can also contribute to staving off some of the margin pressure. MDLZ is largely hedged on its cocoa input costs for 2026 but less so in 2027. Thus, if the substantial rise in cocoa pricing in 2025 does not reemerge, it should help the bottom line in 2027 as cost pressures should ease. Share buybacks have also contributed to EPS, and we note that Q1 2026 share count was down 1.5% from one year earlier.
$MDLZ